QuidelOrtho

QuidelOrtho Corporation is a prominent global in vitro diagnostics (IVD) company, established in 2022 through the merger of Quidel Corporation and Ortho Clinical Diagnostics. With headquarters in San Diego, California, the company boasts over 120 years of combined experience in diagnostic science. QuidelOrtho develops, manufactures, and markets a wide range of diagnostic solutions for various healthcare settings, including clinical laboratories, hospitals, and point-of-care environments. Their offerings include rapid diagnostic tests, molecular PCR assays, immunoassays, and blood typing solutions. Notable products include the first FDA-approved rapid antigen tests for Influenza A and B, as well as for SARS-CoV-2. The company also provides informatics solutions to enhance laboratory capabilities and supports public health efforts with a variety of COVID-19 testing options. With a diverse customer base that includes hospitals, blood banks, and retail pharmacies, QuidelOrtho is dedicated to improving patient outcomes through innovative diagnostic technologies and a commitment to advancing healthcare.

• Employees 6600
• Founded 1937
• Annual Revenue $2782900000
• Total Funding $3400000000